PeptideCompareCJC-1295 (With DAC) — EU research guide.
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with a lysine-maleimide linker that covalently binds to albumin in the bloodstream, extending its half-life from minutes to approximately 7–8 days.
What is CJC-1295 with DAC?
CJC-1295 is a modified GHRH(1-29) analogue. The DAC modification involves substituting Lys30 with a maleimidoproprionic acid group that spontaneously reacts with cysteine-34 of circulating albumin, forming a stable covalent bond. This dramatically extends the half-life to ~7–8 days, allowing once-weekly administration in research protocols and producing sustained GH pulse amplification.
What does the research show?
Human pharmacokinetic studies show sustained GH and IGF-1 elevation after single injection. Compared to CJC-1295 No DAC, the DAC version produces a more sustained but blunted GH pattern rather than the sharp pulsatile release preferred physiologically. Research interest includes GH deficiency models, muscle catabolism prevention and body composition research.
EU legal status
Not approved in the EU. WADA-prohibited in sport (S2 — Peptide hormones). Available for laboratory research only. The sustained-release modification makes it particularly interesting pharmacokinetically but does not change its research-only status.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Estimates modelled per compound from its molecular properties (sequence length, cyclisation, oxidation- and deamidation-prone residues, light sensitivity). Indicative only — not lab-measured per batch.
CJC-1295 (DAC) across EU suppliers
COA-verified EU vendors · Updated monthly
Frequently asked questions
What is CJC-1295 with DAC? ▾
CJC-1295 with DAC is a modified GHRH(1-29) analog where the DAC (Drug Affinity Complex) modification substitutes Lys30 with a maleimidopropionic acid group that covalently binds albumin, extending the half-life to about 7 to 8 days.
How does the DAC modification work? ▾
The added group spontaneously reacts with cysteine-34 of circulating albumin to form a stable covalent bond, which dramatically extends the half-life and allows once-weekly administration in research protocols.
What does the research show? ▾
Human pharmacokinetic studies show sustained GH and IGF-1 elevation after a single injection. Research interest includes GH-deficiency models, muscle-catabolism prevention and body composition.
How does it differ from CJC-1295 No DAC? ▾
The DAC version produces a more sustained but blunted GH pattern rather than the sharp pulsatile release of No DAC, which is preferred physiologically.
Is CJC-1295 with DAC legal in the EU? ▾
It is not approved in the EU and is sold as a research compound for laboratory use only.
Is CJC-1295 banned in sport? ▾
Yes. It appears on the WADA prohibited list (S2).
References
- The human study behind the numbers on this page: two randomised, placebo-controlled ascending-dose trials in healthy adults. A single injection raised GH 2–10× for 6+ days and IGF-1 1.5–3× for 9–11 days; the estimated half-life was 5.8–8.1 days. One of very few GHRH analogues with published human PK. Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799–805. DOIPubMed 16352683